BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 25756049)

  • 41. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
    Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
    Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
    Tunesi S; Ferrante D; Mirabelli D; Andorno S; Betti M; Fiorito G; Guarrera S; Casalone E; Neri M; Ugolini D; Bonassi S; Matullo G; Dianzani I; Magnani C
    Carcinogenesis; 2015 Oct; 36(10):1129-35. PubMed ID: 26139392
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bioinformatic Analysis of Potential Biomarker for hsa-miR-196b-5p in Mesothelioma.
    Sohn EJ
    Genet Test Mol Biomarkers; 2021 Dec; 25(12):772-780. PubMed ID: 34874752
    [No Abstract]   [Full Text] [Related]  

  • 44. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
    Edakuni N; Ikuta K; Yano S; Nakataki E; Muguruma H; Uehara H; Tani M; Yokota J; Aizawa H; Sone S
    Oncol Res; 2006; 16(5):235-43. PubMed ID: 17294804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial.
    Muti P; Sacconi A; Pulito C; Orlandi G; Donzelli S; Morrone A; Jiulian J; Cox GP; Kolb M; Pond G; Kavsak P; Levine MN; Blandino G; Strano S
    J Exp Clin Cancer Res; 2022 Aug; 41(1):255. PubMed ID: 35987988
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma.
    Gee GV; Koestler DC; Christensen BC; Sugarbaker DJ; Ugolini D; Ivaldi GP; Resnick MB; Houseman EA; Kelsey KT; Marsit CJ
    Int J Cancer; 2010 Dec; 127(12):2859-69. PubMed ID: 21351265
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
    Betti M; Casalone E; Ferrante D; Aspesi A; Morleo G; Biasi A; Sculco M; Mancuso G; Guarrera S; Righi L; Grosso F; Libener R; Pavesi M; Mariani N; Casadio C; Boldorini R; Mirabelli D; Pasini B; Magnani C; Matullo G; Dianzani I
    Cancer Lett; 2017 Oct; 405():38-45. PubMed ID: 28687356
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The expression and clinical significance of B7-H3 and miR-145 in lung cancer patients with malignant pleural effusion.
    Huang L
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6759-6766. PubMed ID: 32633367
    [TBL] [Abstract][Full Text] [Related]  

  • 50. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
    Williams M; Kirschner MB; Cheng YY; Hanh J; Weiss J; Mugridge N; Wright CM; Linton A; Kao SC; Edelman JJ; Vallely MP; McCaughan BC; Cooper W; Klebe S; Lin RC; Brahmbhatt H; MacDiarmid J; van Zandwijk N; Reid G
    Oncotarget; 2015 Sep; 6(27):23480-95. PubMed ID: 26125439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modulation of microRNA expression levels after naturally occurring asbestiform fibers exposure as a diagnostic biomarker of mesothelial neoplastic transformation.
    Filetti V; Falzone L; Rapisarda V; Caltabiano R; Eleonora Graziano AC; Ledda C; Loreto C
    Ecotoxicol Environ Saf; 2020 Jul; 198():110640. PubMed ID: 32330788
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Iron signature in asbestos-induced malignant pleural mesothelioma: A population-based autopsy study.
    Crovella S; Bianco AM; Vuch J; Zupin L; Moura RR; Trevisan E; Schneider M; Brollo A; Nicastro EM; Cosenzi A; Zabucchi G; Borelli V
    J Toxicol Environ Health A; 2016; 79(3):129-41. PubMed ID: 26818092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.
    De Santi C; Melaiu O; Bonotti A; Cascione L; Di Leva G; Foddis R; Cristaudo A; Lucchi M; Mora M; Truini A; Tironi A; Murer B; Boldorini R; Cipollini M; Gemignani F; Gasparini P; Mutti L; Landi S
    Sci Rep; 2017 Jun; 7(1):3140. PubMed ID: 28600498
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Four-miRNA Signature to Identify Asbestos-Related Lung Malignancies.
    Santarelli L; Gaetani S; Monaco F; Bracci M; Valentino M; Amati M; Rubini C; Sabbatini A; Pasquini E; Zanotta N; Comar M; Neuzil J; Tomasetti M; Bovenzi M
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):119-126. PubMed ID: 30257964
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and prognostic features of erionite-induced malignant mesothelioma.
    Demirer E; Ghattas CF; Radwan MO; Elamin EM
    Yonsei Med J; 2015 Mar; 56(2):311-23. PubMed ID: 25683976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanism of miR-222 and miR-126 regulation and its role in asbestos-induced malignancy.
    Gaetani S; Monaco F; Alessandrini F; Tagliabracci A; Sabbatini A; Bracci M; Valentino M; Neuzil J; Amati M; Santarelli L; Tomasetti M
    Int J Biochem Cell Biol; 2020 Apr; 121():105700. PubMed ID: 32006662
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
    Creaney J; Dick IM; Segal A; Musk AW; Robinson BW
    Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.
    Sneddon S; Patch AM; Dick IM; Kazakoff S; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
    BMC Cancer; 2017 Jun; 17(1):396. PubMed ID: 28577549
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-Hodgkin Lymphoma and Pleural Mesothelioma in a Person Exposed to Asbestos.
    Bianchi C; Bianchi T
    Turk Patoloji Derg; 2018; 34(2):190-193. PubMed ID: 28272659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
    Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
    Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.